Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
← catalyst calendarNCT06617169 · readout ≤ 134 d
Sponsored by Monopar Therapeutics (industry) · MNPR — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
12estimated
Sites
1
Country
Australia
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-10-08 | actual | When the study began enrolling |
| Primary completion | Dec 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-05-21 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Solid Tumor, Adult
- Bladder Cancer
- Urothelial Carcinoma
- Triple-negative Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Gastric Cancer
- Ovarian Cancer
- Pancreatic Cancer
Intervention
- Drug: MNPR-101-PCTA-177Lu
Primary outcomes
what the primary-completion date above is the date OFIdentify the dose-limiting toxicities (DLTs) of fractionated MNPR-101-PCTA-177Lu dosing and their frequency
measured For 6 weeks after the first dose
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] of fractionated MNPR-101-PCTA-177Lu dosing
measured From dosing to the End of Study at 24 weeks
Permalink · MNPR's whole pipeline · Catalyst calendar · Every registered study · What changed